| Literature DB >> 25098613 |
Shanta Dutta1, Surojit Das1, Utpala Mitra1, Priyanka Jain1, Indranil Roy2, Shelley S Ganguly3, Ujjwayini Ray4, Phalguni Dutta1, Dilip Kumar Paul5.
Abstract
Enteric fever, caused by Salmonella enterica, remains an unresolved public health problem in India and antimicrobial therapy is the main mode of treatment. The objective of this study was to characterize the Salmonella enterica isolates from Kolkata with respect to their antimicrobial resistance (AMR), virulence profiles and molecular subtypes. Salmonella enterica blood isolates were collected from clinically suspected enteric fever patients attending various hospitals in Kolkata, India from January 2009 to June 2013 and were tested for AMR profiles by standard protocols; for resistance gene transfer by conjugation; for resistance and virulence genes profiles by PCR; and for molecular subtypes by Pulsed Field Gel Electrophoresis (PFGE). A total of 77 Salmonella enterica serovar Typhi (S. Typhi) and 25 Salmonella enterica serovar Paratyphi A (S. Paratyphi A) from Kolkata were included in this study. Although multidrug resistance (resistance to chloramphenicol, ampicillin, co-trimoxazole) was decreasing in S. Typhi (18.2%) and absent in S. Paratyphi A, increased resistance to fluoroquinolone, the current drug of choice, caused growing concern for typhoid treatment. A single, non-conjugative non-IncHI1 plasmid of 180 kb was found in 71.4% multidrug resistant (MDR) S. Typhi; the remaining 28.6% isolates were without plasmid. Various AMR markers (blaTEM-1, catA, sul1, sul2, dfrA15, strA-strB) and class 1 integron with dfrA7 gene were detected in MDR S. Typhi by PCR and sequencing. Most of the study isolates were likely to be virulent due to the presence of virulence markers. Major diversity was not noticed among S. Typhi and S. Paratyphi A from Kolkata by PFGE. The observed association between AMR profiles and S. Typhi pulsotypes might be useful in controlling the spread of the organism by appropriate intervention. The study reiterated the importance of continuous monitoring of AMR and molecular subtypes of Salmonella isolates from endemic regions for better understanding of the disease epidemiology.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25098613 PMCID: PMC4123848 DOI: 10.1371/journal.pone.0101347
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Primers list for detection of resistance genes in S. Typhi Kolkata isolates.
| Resistance Gene | Oligonucleotide sequences (5′→3′) | PCR Product size (bp) | Reference |
|
|
| 798 |
|
|
|
| 813 |
|
|
|
| 885 |
|
|
|
| 293 |
|
|
|
| 789 |
|
|
|
| 722 |
|
|
|
| 990 |
|
|
|
| 474 |
|
|
|
| 937 |
|
|
|
| 416 |
|
|
|
| 548 |
|
|
|
| 509 |
|
|
|
| 528 |
|
|
|
| 483 |
|
|
|
| variable |
|
|
|
| 287 |
|
Year wise distribution of antimicrobial resistant S. Typhi and S. Paratyphi A Kolkata isolates, 2009 to 2013.
| Antimicrobial resistance Groups |
|
| ||||||
| 2009–2011 (n = 22) | 2012 (n = 27) | 2013 (n = 28) | Total (n = 77) | 2009–2011 (n = 7) | 2012 (n = 9) | 2013 (n = 9) | Total (n = 25) | |
|
| 3(13.6) | 4(14.8) | 7(25) |
| 0 | 0 | 0 |
|
|
| 22(100) | 26(96.3) | 28(100) |
| 6(85.7) | 9(100) | 9(100) |
|
|
| 16(72.7) | 22(81.5) | 23(82.1) |
| 5(71.4) | 7(77.8) | 7(77.8) |
|
|
| 6(27.3) | 4(14.8) | 5(17.9) |
| 1(14.3) | 2(22.2) | 2(22.2) |
|
MDR, multidrug resistant (resistance to ampicillin, chloramphenicol, co-trimoxazole with or without tetracycline).
NaR, nalidixic acid resistant.
DCS, decreased susceptibility to ciprofloxacin.
CiR, ciprofloxacin resistant.
All data are in no. (%).
Figure 1Percentage distribution of antimicrobial resistance in S. Typhi and S. Paratyphi A Kolkata isolates during 2009–2013.
Interpretation was based on the MIC values of the antimicrobials. A, ampicillin; C, chloramphenicol; Q, co-trimoxazole; T, tetracycline; S, streptomycin; Na, nalidixic acid; Ci, ciprofloxacin; Of, ofloxacin; Le, levofloxacin; Az, azithromycin, Ac, amoxicillin/clavulanic acid.
MIC50 and MIC90 of S. Typhi (n = 77) and S. Paratyphi A (n = 25) isolates from Kolkata, 2009 to 2013.
| Antimicrobial agents | MIC Range (µg/ml) | MIC50 (µg/ml) | MIC90 (µg/ml) | MIC (µg/ml) breakpoint for resistance | |||
| ST | SPA | ST | SPA | ST | SPA | ||
| Ampicillin | 0.094–≥256 | 1–3 | 0.5 | 1.5 | ≥256 | 3 |
|
| Chloramphenicol | 1.5–≥256 | 4–8 | 2 | 6 | ≥256 | 8 |
|
| Co-trimoxazole | 0.008–≥32 | 0.032–0.125 | 0.023 | 0.094 | ≥32 | 0.125 |
|
| Tetracycline | 1–16 | 1.5–4 | 1.5 | 3 | 3 | 4 |
|
| Nalidixic acid | 2–≥256 | 1.5–≥256 | ≥256 | ≥256 | ≥256 | ≥256 |
|
| Ciprofloxacin | 0.064–≥32 | 0.032–0.75 | 0.38 | 0.5 | ≥32 | 0.75 |
|
| Ofloxacin | 0.047–≥32 | 0.125–4 | 0.75 | 2 | 24 | 3 |
|
| Levofloxacin | 0.023–24 | 0.064–1 | 0.25 | 0.75 | 4 | 1 |
|
| Ceftriaxone | 0.032–0.19 | 0.064–0.19 | 0.064 | 0.125 | 0.125 | 0.19 |
|
| Ceftazidime | 0.064–0.38 | 0.19–0.75 | 0.19 | 0.38 | 0.38 | 0.5 |
|
| Cefotaxime | 0.023–0.125 | 0.125–0.25 | 0.064 | 0.19 | 0.094 | 0.19 |
|
| Azithromycin | 1.5–16 | 3–32 | 8 | 16 | 12 | 32 | >16 |
| Amoxicillin/clavulanic acid | 0.25–≥256 | 0.75–3 | 0.5 | 1.5 | 32 | 1.5 |
|
ST, S. Typhi.
SPA, S. Paratyphi A.
CLSI, 2013 guideline followed for all antimicrobials except azithromycin.
Figure 2MIC distributions of fluoroquinolones and azithromycin in all S. Typhi and S. Paratyphi A Kolkata Isolates during 2009–2013.
Interrupted lines denote MIC breakpoints of the antimicrobials for susceptible (left line) and resistant (Right Line) isolates. Isolates having MICs between two Interrupted lines showed reduced susceptibility. For azithromycin, single interrupted line indicates MIC breakpoint (>16 µg/ml) of resistance.
Antimicrobial resistance profiles of S. Typhi and S. Paratyphi A Kolkata isolates from 2009–2013.
| Antimicrobial resistance profile |
|
|
| Na | 45(58.4) | 10(40) |
| Na/Ci/Of/Le | 13(16.9) | 0 |
| A/C/Q/S/Na/Ac | 7(9.1) | 0 |
| A/C/Q/S/Na | 6(7.8) | 0 |
| C/Q/Na | 3(3.9) | 0 |
| A/C/Q/S/Na/Ci/Ac | 1(1.3) | 0 |
| T/Q/Na/Ci/Of/Le | 1(1.3) | 0 |
| Na/Of | 0 | 5(20) |
| Na/Of/Az | 0 | 4(16) |
| Na/Ci/Of | 0 | 3(12) |
| Na/Ci/Of/Az | 0 | 2(8) |
All data are in no. (%); Abbreviations used: A, ampicillin; C, chloramphenicol; Q, co-trimoxazole; T, tetracycline; S, streptomycin; Na, nalidixic acid; Ci, ciprofloxacin; Of, ofloxacin; Le, levofloxacin; Az, azithromycin; Ac, amoxicillin/clavulanic acid.
associated with decreased susceptibility to ciprofloxacin (DCS); One isolate in each serovar was susceptible to all antimicrobials tested.
Phenotypic and molecular characteristics of drug resistant S. Typhi (n = 18) isolates from Kolkata during 2009–2013.
| Antimicrobialresistancegroup | SampleID no | R profile (n) | Plasmid (size) | Transfer ofresistancegenes byconjugation | Screening of resistance genes by PCR | ||||||||
|
|
|
|
|
|
|
|
| Class 1integron | |||||
| MDR | BCR49 | A/C/Q/S/Na | 180 kb | − | + | + | + | + | − | − | + | + | + |
| KOL34 | (n = 6) | 180 kb | − | + | + | + | + | − | − | + | + | + | |
| KOL61 | 180 kb | − | + | + | + | + | − | − | + | + | + | ||
| KOL62 | 180 kb | − | + | + | + | + | − | − | + | + | + | ||
| SP47 | Absent | ND | + | + | + | + | − | − | + | + | + | ||
| KOL39 | Absent | ND | + | + | + | + | − | − | + | + | + | ||
| BCR305 | A/C/Q/S/Na/Ac | 180 kb | − | + | + | + | + | − | − | + | + | + | |
| BCR342 | (n = 7) | 180 kb | − | + | + | + | + | − | − | + | + | + | |
| KOL17 | 180 kb | − | + | + | + | + | − | − | + | + | + | ||
| KOL18 | 180 kb | − | + | + | + | + | − | − | + | + | + | ||
| KOL38 | 180 kb | − | + | + | + | + | − | − | + | + | + | ||
| KOL31 | Absent | ND | + | + | + | + | − | − | + | + | + | ||
| KOL37 | Absent | ND | + | + | + | + | − | − | + | + | + | ||
| BCR177 | A/C/Q/S/Na/Ci/Ac | 180 kb | − | + | + | + | + | − | − | + | + | + | |
| Non MDR | KOL 36 | C/Q/Na | 180 kb | − | − | + | + | − | − | − | − | − | + |
| KOL 42 | (n = 3) | 180 kb | − | − | + | + | − | − | − | − | − | + | |
| KOL 58 | 180 kb | − | − | + | + | − | − | − | − | − | + | ||
| KOL 33 | T/Q/S/Na/Ci/Of/Le | 50 kb | + | − | − | + | − | + | + | − | − | + | |
Abbreviations used: MDR, multidrug resistant; ND, not done; A, ampicillin; C, chloramphenicol; Q, co-trimoxazole; T, tetracycline; S, streptomycin; Na, nalidixic acid; Ci, ciprofloxacin; Of, ofloxacin; Le, levofloxacin; Ac, amoxicillin/clavulanic acid.
all isolates were negative for bla OXA, bla SHV and sul3 genes by PCR.
possessed dfrA7 gene cassette as determined by sequencing of 750 bp PCR amplicon.
plasmid type: IncN; tetA was positive, but tetB was negative by PCR; transfer of tetA, sul1, dfrA15 and aadA1 genes by conjugation.
gene cassette could not be determined by sequencing of 1.6 kb PCR amplicon.
Virulence gene profiles by PCR of S. Typhi and S. Paratyphi A Kolkata isolates, 2009–2013.
| Virulencegenes | Function | Oligonucleotide sequences (5′→3′) | PCR productsize (bp) | Positive by PCR | Reference | |
|
|
| |||||
|
| Delivery of type IIIsecreted effectors |
| 500 | 55 | 21 |
|
|
| Invasion proteintranscriptionalactivator |
| 207 | 55 | 21 | This study |
|
| Type III secretorypathway protein |
| 677 | 45 | 21 |
|
|
| DNA-bindingresponse regulator intwo-componentregulatory system |
| 322 | 55 | 21 | This study |
|
| Intracellular survivaland growth in lowMg2+ environmentsduring systemicphase of the disease |
| 478 | 55 | 21 | This study |
|
| TypeI secretionprotein necessaryfor the secretion ofSpi4E |
| 1231 | 53 | 19 |
|
|
| Mediatesinflammation andfluid secretion inintestinal mucosa |
| 214 | 55 | 21 | This study |
|
| Type VI secretionlipoprotein |
| 433 | 55 | 21 | This study |
|
| Periplasmicfimbrialchaperone protein |
| 316 | 55 | 21 | This study |
|
| Vi polysaccharidebiosynthesis protein |
| 460 | 55 | ND |
|
|
| Enterotoxin |
| 617 | 52 | 21 |
|
|
| Delivery of CdtBfrom intracellularcompartment totarget cells |
| 343 | 55 | 21 | This study |
ND, not done.
Figure 3Dendrogram showing the cluster analysis of 76 S. Typhi isolates from Kolkata, India, 2009–2013, by XbaI-PFGE.
Band comparison was performed by using the Dice coefficient with 1.5% optimization (Opt) and 1.5% position tolerance (Tol). Pan-susceptible, susceptible to all 17 drugs tested; A, ampicillin; Ac, amoxicillin/clavulanic acid; C, chloramphenicol; Q, co-trimoxazole; T, tetracycline; S, streptomycin; Na, nalidixic acid; Ci, ciprofloxacin; Of, ofloxacin; Le, levofloxacin.
Figure 4Dendrogram showing the cluster analysis of 24 S. Paratyphi A isolates from Kolkata, India, 2009–2013, by XbaI-PFGE.
Band comparison was performed by using the Dice coefficient with 1.5% optimization (Opt) and 1.5% position tolerance (Tol). Pan-susceptible, susceptible to all 17 drugs tested; Na, nalidixic acid; Ci, ciprofloxacin; Of, ofloxacin; Az, azithromycin.